- Home
- GFAI vs BIVI Comparison
GFAI vs BIVI Comparison
Compare GFAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- BIVI
- Stock Information
- Founded
- GFAI 2018
- BIVI 2013
- Country
- GFAI Singapore
- BIVI United States
- Employees
- GFAI N/A
- BIVI N/A
- Industry
- GFAI Diversified Commercial Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- BIVI Health Care
- Exchange
- GFAI Nasdaq
- BIVI Nasdaq
- Market Cap
- GFAI 20.7M
- BIVI 18.6M
- IPO Year
- GFAI N/A
- BIVI N/A
- Fundamental
- Price
- GFAI $1.15
- BIVI $1.01
- Analyst Decision
- GFAI Strong Buy
- BIVI Strong Buy
- Analyst Count
- GFAI 1
- BIVI 1
- Target Price
- GFAI $4.50
- BIVI $30.00
- AVG Volume (30 Days)
- GFAI 367.3K
- BIVI 906.1K
- Earning Date
- GFAI 04-28-2025
- BIVI 05-12-2025
- Dividend Yield
- GFAI N/A
- BIVI N/A
- EPS Growth
- GFAI N/A
- BIVI N/A
- EPS
- GFAI N/A
- BIVI N/A
- Revenue
- GFAI $36,347,373.00
- BIVI N/A
- Revenue This Year
- GFAI $5.66
- BIVI N/A
- Revenue Next Year
- GFAI $4.69
- BIVI N/A
- P/E Ratio
- GFAI N/A
- BIVI N/A
- Revenue Growth
- GFAI 0.18
- BIVI N/A
- 52 Week Low
- GFAI $0.76
- BIVI $0.62
- 52 Week High
- GFAI $3.88
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- GFAI 53.79
- BIVI 52.61
- Support Level
- GFAI $1.11
- BIVI $1.02
- Resistance Level
- GFAI $1.33
- BIVI $1.07
- Average True Range (ATR)
- GFAI 0.08
- BIVI 0.07
- MACD
- GFAI 0.01
- BIVI -0.01
- Stochastic Oscillator
- GFAI 37.93
- BIVI 31.17
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.